Observational studyThe British journal of dermatology2022
The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care.
Observational study in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04239521 (The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata), which is not on this map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- A systematic review and meta-synthesis of qualitative studies of alopecia: Managing identity and appearance changes.British journal of health psychology · 2026Pooled it
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Anxiety, depression, and quality of life in children and adults with alopecia areata: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Identifying and addressing obstacles to optimal alopecia areata and atopic dermatitis care in the UK.Skin health and disease · 2026Article
- Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study.The Australasian journal of dermatology · 2026Article
- Association of Janus kinase inhibitors with reduced depression in alopecia areata.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Unraveling microbial signatures in the comorbidity of autoimmune diseases and depression.BMC microbiology · 2026Article
- An occupational perspective of the lived experience of individuals with Alopecia Areata: A scoping review.The British journal of occupational therapy · 2026Review
- Real-World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction.The Journal of dermatology · 2026Article
- Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA.Dermatology and therapy · 2026Article
- Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.Dermatology and therapy · 2026Article
- Importance of alexithymia on anxiety and depression in alopecia areata: a cohort study.Skin health and disease · 2026Article
- Illness Perception, Emotional Distress, and Obsessive-Compulsive Symptomatology in Patients with Alopecia Areata: A Mediation Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- Beyond skin deep: self-compassion mediates the link between body shame and psychopathology in people with alopecia and psoriasis.Health psychology report · 2026Article
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics.Frontiers in medicine · 2026Review
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges - A Narrative Review.Journal of inflammation research · 2026Review
- The Psychiatric Burden in Alopecia Areata: A Propensity-Matched Cohort Study.Dermatology and therapy · 2026Article
- Genome-wide association study of atopic and autoimmune comorbidities in alopecia areata.Frontiers in immunology · 2026Article
- The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review.Dermatology and therapy · 2025Review
- Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundAlopecia areata (AA) is a common cause of nonscarring hair loss that can have a profound psychological impact.
objectivesTo assess the co-occurrence of depression and anxiety in adults with AA compared with the general population, and to evaluate the mental health treatment burden and impact on time off work and unemployment.
methodsIn total, 5435 people with newly diagnosed AA in UK primary care were identified from the Oxford Royal College of General Practitioners Research and Surveillance Centre network database, and matched to 21 740 controls. In cases and controls, we compared the prevalence and incidence of depressive episodes, recurrent depressive disorder and anxiety disorder, rates of time off work and unemployment, and, in those with pre-existing mental health conditions, rates of mental health-related prescribing and referral rates. This observational was registered with ClinicalTrials.gov (NCT04239521).
resultsDepression and anxiety were more prevalent in people diagnosed with AA than in controls (P < 0·001). People with AA were also more likely to subsequently develop new-onset depression and anxiety: adjusted hazard ratio (aHR) for recurrent depressive disorder 1·38 [95% confidence interval (CI) 1·13-1·69], depressive episodes aHR 1·30 (95% CI 1·04-1·62) and anxiety disorder aHR 1·33 (95% CI 1·09-1·63); to be issued time off work certificates (aHR 1·56, 95% CI 1·43-1·71); and to be recorded as unemployed (aHR 1·82, 95% CI 1·33-2·49). Higher rates of antidepressant prescribing were also seen in people with AA.
conclusionsPeople with AA have higher rates of depression and anxiety than those without AA. This impacts deleteriously on mental health treatment burden, time off work and unemployment. Evidence-based mental health treatment programmes are needed for people with AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.